Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake

Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis

(2017) Yasushi Okura et al.   HEPATOLOGY RESEARCH

Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway

(2017) Hsin-Hwa Tsai et al.   Oncotarget

Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice

(2017) Koki Obara et al.   Oncotarget

Intestinal SGLT1 in metabolic health and disease

(2016) Anders Lehmann et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Glycolytic regulation of cell rearrangement in angiogenesis

(2016) Bert Cruys et al.   Nature Communications

The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration

(2016) Linda A. Villani et al.   Molecular Metabolism

Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer

(2015) S. Jain et al.   CANCER RESEARCH

Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy

(2015) Rosa Barreira da Silva et al.   NATURE IMMUNOLOGY

Functional expression of sodium-glucose transporters in cancer

(2015) Claudio Scafoglio et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogene Pathway Activation in Mammary Tumors Dictates FDG-PET Uptake

(2014) J. V. Alvarez et al.   CANCER RESEARCH

Blocking Lactate Export by Inhibiting the Myc Target MCT1 Disables Glycolysis and Glutathione Synthesis

(2013) J. R. Doherty et al.   CANCER RESEARCH

Role of PFKFB3-Driven Glycolysis in Vessel Sprouting

(2013) Katrien De Bock et al.   CELL

Prognostic Significance of AMPK Activation and Therapeutic Effects of Metformin in Hepatocellular Carcinoma

(2013) L. Zheng et al.   CLINICAL CANCER RESEARCH

Oxygen-independent Regulation of HIF-1: Novel Involvement of PI3K/ AKT/mTOR Pathway in Cancer

(2013) Faton Agani et al.   CURRENT CANCER DRUG TARGETS

Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force

(2013) F. Polet et al.   JOURNAL OF INTERNAL MEDICINE

SGLT inhibitors in management of diabetes

(2013) Abd A Tahrani et al.   Lancet Diabetes & Endocrinology

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

(2012) Hsiao-Ping Chen et al.   GUT

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

(2012) Jordi Bruix et al.   JOURNAL OF HEPATOLOGY

Hepatocellular carcinoma

(2012) Alejandro Forner et al.   LANCET

Lactate Influx through the Endothelial Cell Monocarboxylate Transporter MCT1 Supports an NF- B/IL-8 Pathway that Drives Tumor Angiogenesis

(2011) F. Vegran et al.   CANCER RESEARCH

Basic fibroblast growth factor regulates glucose metabolism through glucose transporter 1 induced by hypoxia-inducible factor-1α in adipocytes

(2011) Yoshitaka Kihira et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

ATP Consumption Promotes Cancer Metabolism

(2010) William J. Israelsen et al.   CELL

SGLT2 inhibition — a novel strategy for diabetes treatment

(2010) Edward C. Chao et al.   NATURE REVIEWS DRUG DISCOVERY

GLUT1 Expression Is Increased in Hepatocellular Carcinoma and Promotes Tumorigenesis

(2009) Thomas Amann et al.   AMERICAN JOURNAL OF PATHOLOGY

Cancer Cell Metabolism: Warburg and Beyond

(2008) Peggy P. Hsu et al.   CELL

The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation

(2008) Ralph J. DeBerardinis et al.   Cell Metabolism

Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus

(2008) Bart J. Veldt et al.   HEPATOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE